Efficacy and safety of the long-acting β(2)-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease

BACKGROUND: Olodaterol is a novel long-acting β(2)-agonist with proven ≥24-hour duration of action in preclinical and clinical studies. OBJECTIVE: This randomized, double-blind, placebo-controlled, parallel-group study evaluated the dose response of once-daily (QD) olodaterol based on bronchodilator...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichinose, Masakazu, Takizawa, Ayako, Izumoto, Toshiyasu, Tadayasu, Yusuke, Hamilton, Alan L, Kunz, Christina, Fukuchi, Yoshinosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548739/
https://www.ncbi.nlm.nih.gov/pubmed/26316741
http://dx.doi.org/10.2147/COPD.S86002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548739/
https://www.ncbi.nlm.nih.gov/pubmed/26316741
http://dx.doi.org/10.2147/COPD.S86002

Ejemplares similares